Literature DB >> 9491817

Serum leptin levels increase rapidly after initiation of clozapine therapy.

T Brömel1, W F Blum, A Ziegler, E Schulz, M Bender, C Fleischhaker, H Remschmidt, J C Krieg, J Hebebrand.   

Abstract

Weight gain is a major side-effect of treatment with clozapine. In order to investigate the influence of the atypical neuroleptic clozapine on leptin secretion, serum leptin levels were measured in 12 patients at baseline and for a 10-week period after initiation of treatment. Serum clozapine levels and levels of its metabolites were simultaneously assessed. Alterations of body weight and body composition were determined. During the 10-week observation period leptin levels differed significantly from the levels determined at baseline (P < 0.0001). During the first 2 weeks of treatment serum leptin levels at least doubled in eight of the 12 patients. The maximal relative increase over baseline was 536%. Low doses of clozapine were sufficient to induce this effect. Within a 10-week period mean body weight, mean body mass index, mean fat mass and mean lean body mass all increased. Based on the results we suggest that in predisposed individuals clozapine induces an increased appetite; overeating and weight gain can ensue, which in turn underlie elevated leptin secretion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491817     DOI: 10.1038/sj.mp.4000352

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  25 in total

Review 1.  Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology.

Authors:  L E Arnold; M G Aman; A Martin; A Collier-Crespin; B Vitiello; E Tierney; R Asarnow; F Bell-Bradshaw; B J Freeman; P Gates-Ulanet; A Klin; J T McCracken; C J McDougle; J J McGough; D J Posey; L Scahill; N B Swiezy; L Ritz; F Volkmar
Journal:  J Autism Dev Disord       Date:  2000-04

2.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

Authors:  R Coccurello; A Caprioli; O Ghirardi; R Conti; B Ciani; S Daniele; A Bartolomucci; A Moles
Journal:  Psychopharmacology (Berl)       Date:  2006-05-13       Impact factor: 4.530

3.  A prospective study of serum ghrelin levels in patients treated with clozapine.

Authors:  F M Theisen; S Gebhardt; T Brömel; B Otto; W Heldwein; M Heinzel-Gutenbrunner; J-C Krieg; H Remschmidt; M Tschöp; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 4.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

5.  Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders.

Authors:  S Gebhardt; M Haberhausen; J-C Krieg; H Remschmidt; M Heinzel-Gutenbrunner; J Hebebrand; F M Theisen
Journal:  J Neural Transm (Vienna)       Date:  2007-03-20       Impact factor: 3.575

Review 6.  Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

Authors:  James L Roerig; Kristine J Steffen; James E Mitchell
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 7.  Bodyweight gain with atypical antipsychotics. A comparative review.

Authors:  T Wetterling
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

8.  Glucose intolerance with atypical antipsychotics.

Authors:  Karin Hedenmalm; Staffan Hägg; Malin Ståhl; Orjan Mortimer; Olav Spigset
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

10.  The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs.

Authors:  Aliye Ozenoglu; Huriye Balci; Serdal Ugurlu; Erkan Caglar; Hafize Uzun; Cihat Sarkis; Can Gunay; Engin Eker E
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.